Telmisartan (Micardis)

A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.

Also Known As:

Micardis; Pritor; 4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; BIBR 277; BIBR-277; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-

Networked: 1345 relevant articles (245 outcomes, 541 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Yusuf, Salim: 45 articles (01/2021 - 01/2002)
2.	Schumacher, Helmut: 26 articles (01/2021 - 01/2002)
3.	Mancia, Giuseppe: 21 articles (01/2021 - 03/2008)
4.	Teo, Koon K: 21 articles (01/2021 - 04/2008)
5.	Teo, Koon: 21 articles (01/2020 - 07/2004)
6.	Schmieder, Roland E: 20 articles (01/2021 - 11/2004)
7.	Gao, Peggy: 20 articles (01/2017 - 10/2009)
8.	Unger, Thomas: 19 articles (01/2017 - 05/2003)
9.	Mann, Johannes F E: 16 articles (01/2022 - 08/2008)
10.	Böhm, Michael: 16 articles (01/2021 - 09/2006)

Related Diseases

1.	Hypertension (High Blood Pressure) 07/01/2004 - "In Japanese patients with mild-moderate hypertension, telmisartan produced a significant reduction in blood pressure (effective rate: 76.0%) with a good safety profile. " 07/01/2004 - "Therefore, telmisartan is expected to be effective in the treatment of hypertension, producing sustained 24-h blood pressure control." 03/01/2012 - "An effort was made to formulate a fast dissolving film containing telmisartan which is used in the treatment of hypertension with a view to improve the onset of action, therapeutic efficacy, patient compliance and convenience. " 12/01/2011 - "This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications. " 01/01/2009 - "Telmisartan provides effective treatment of hypertension in a broad spectrum of patients. "
2.	Insulin Resistance 08/01/2007 - "Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. " 06/01/2013 - "In view of this improved responsiveness to insulin sensitivity, telmisartan may prove to be a promising candidate for the intervention treatment of the pre-diabetes state." 11/08/2012 - "Telmisartan treatment improved insulin sensitivity in obese db/db mice fed a high-fat diet and led to reduction in the size of hypertrophic pancreatic islets in these mice. " 06/01/2012 - "FPI and insulin resistance may be improved with 80 mg of telmisartan." 01/01/2011 - "Treatment with telmisartan not only decreased SBP and DBP levels, but also improved insulin resistance and microalbuminuria by T1. "
3.	Inflammation (Inflammations) 01/01/2020 - "Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells." 08/30/2019 - "Importantly, vascular dysfunction, as assessed by isometric tension studies of isolated aortic rings, vascular inflammation measured by flow cytometry analysis of CD45+CD11b+ immune cells, as well as the increased peripheral oxidative stress levels assessed by L-012-enhanced chemiluminescence were not attenuated by telmisartan treatment of K14-IL-17Aind/+ mice, nor was the persisting skin inflammation. " 01/01/2011 - "The present study was designed to evaluate the dose-response relationship of the anti-inflammatory activity of telmisartan in rat models of chronic inflammation. " 08/30/2019 - "Telmisartan Lowers Elevated Blood Pressure in Psoriatic Mice without Attenuating Vascular Dysfunction and Inflammation." 02/05/2015 - "Telmisartan treatment significantly prevented MAPK mediated inflammation and apoptosis. "
4.	Essential Hypertension 05/01/2009 - "These results suggest that telmisartan is effective in improving endothelial function and arterial stiffness in patients with essential hypertension." 08/01/2006 - "Renal and vascular protective effects of telmisartan in patients with essential hypertension." 10/01/2007 - ": In our study cohort of patients with essential hypertension, treatment with telmisartan improved FMD but did not change RVRI. " 10/01/2007 - "Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension." 01/01/2008 - "To study hypotensive effectiveness and organ-protective properties of telmisartan in patients with essential hypertension (EH). "
5.	Proteinuria 07/01/2021 - "Telmisartan can be effective for the treatment of proteinuria in dogs. " 05/01/2021 - "Erratum for "Efficacy of telmisartan for the treatment of persistent renal proteinuria in dogs: A double-masked, randomized clinical trial"." 11/01/2020 - "Efficacy of telmisartan for the treatment of persistent renal proteinuria in dogs: A double-masked, randomized clinical trial." 07/01/2021 - "Treatment of proteinuria in dogs with telmisartan: A retrospective study." 10/01/2010 - "In addition to providing 24-hour blood pressure control, clinical studies in patients with diabetes show that telmisartan improves renal endothelial function, prevents progression from microalbuminuria to macroalbuminuria, slows the decline in glomerular filtration rate and reduces proteinuria in overt nephropathy. "

Related Drugs and Biologics

1.	Angiotensin Receptor Antagonists
2.	Ramipril (Altace)
3.	Antihypertensive Agents (Antihypertensives)
4.	Losartan (Cozaar)
5.	Amlodipine (Norvasc)
6.	Hydrochlorothiazide (Esidrix)
7.	Glucose (Dextrose)
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
9.	Enalapril
10.	PPAR gamma

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Glycemic Control
4.	Aftercare (After-Treatment)
5.	Highly Active Antiretroviral Therapy (HAART)